m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00461
 [1], [2], [3]
RNA modification MIR149 MIR149 ADAR Methylation : modification sites Indirect Enhancement m6A modification CSF1 CSF1 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Macrophage colony-stimulating factor 1 (CSF1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target MicroRNA 149 (MIR149) View Details
Crosstalk Relationship A-to-I  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary ADAR1 interacts with MicroRNA 149 (MIR149), increasing it's A-to-I level and promoting its physical interaction with Macrophage colony-stimulating factor 1 (CSF1), which was regulated by METTL3-mediated m6A modification.
In-vitro Model
 TOV-112D Ovarian endometrioid adenocarcinoma Homo sapiens CVCL_3612
BRO Amelanotic melanoma Homo sapiens CVCL_7036
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Macrophage colony-stimulating factor 1 (CSF1) 4 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name RG7155 Phase 2 [4]
MOA Antagonist
External Link
TTD: D06NQH
 Compound Name Emactuzumab Phase 1 [5]
MOA Antagonist
External Link
TTD: D00MJI
 Compound Name PLX73086 Phase 1 [4]
MOA Antagonist
External Link
TTD: D0PL8D
 Compound Name MSC110 Phase 1 [6]
Synonyms
Lacnotuzumab
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D18QIB
References
Ref 1 METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol Int. 2020 Dec;44(12):2524-2531. doi: 10.1002/cbin.11459. Epub 2020 Sep 11.
Ref 2 ADAR1p150 regulates the biosynthesis and function of miRNA-149* in human melanoma. Biochem Biophys Res Commun. 2020 Mar 19;523(4):900-907. doi: 10.1016/j.bbrc.2019.12.110. Epub 2020 Jan 17.
Ref 3 miR-149 Suppresses Breast Cancer Metastasis by Blocking Paracrine Interactions with Macrophages. Cancer Res. 2020 Mar 15;80(6):1330-1341. doi: 10.1158/0008-5472.CAN-19-1934. Epub 2020 Jan 7.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 6 Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.